MedPath

To Investigate the Efficacy and Safety of OPC-6535 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Phase 2
Completed
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Registration Number
NCT00917150
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Brief Summary

To investigate the efficacy and safety of OPC-6535 in COPD patients, using the measurement of trough FEV1 over time as the primary endpoint.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
771
Inclusion Criteria
  • Age 40 to 75 years, inclusive, at the time informed consent is obtained
  • Ability to provide own written informed consent
  • Agree to use an appropriate method of contraception until 3 months after the last dose of the investigational medicinal product (IMP)
  • A rating of 1 or higher on the Goddard scale in assessment of emphysema severity by chest CT scan at screening
  • Ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) of less than 70% at screening
  • Cigarette smoking history of at least 20 pack years at screening
Exclusion Criteria
  • Subjects with obstructive disorders due to bronchial asthma
  • Subjects receiving long-term oxygen therapy
  • Subjects with active tuberculosis or obvious bronchiectasis
  • Complication of malignant tumor
  • Uncontrolled cardiovascular, endocrine, blood, or nervous system disorders
  • Uncontrolled condition with COPD exacerbation of level 2 or 3 within 8 weeks prior to the start of washout period (within 12 weeks prior to start of treatment period)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
placeboplacebo-
OPC-6535 25mgtetomilast (OPC-6535)-
OPC-6535 50mgtetomilast (OPC-6535)-
OPC-6535 12.5mgtetomilast (OPC-6535)-
Primary Outcome Measures
NameTimeMethod
Trough Forced Expiratory Volume in 1 Second (FEV1) Change From Baseline to 24 MonthsBaseline, 24 months

Measurement over time (from baseline over the 24-month treatment period) and change from baseline to end of the treatment period.

Secondary Outcome Measures
NameTimeMethod
Change From Baseline at 24 Months in Total Symptom Diary ScoreBaseline, 24 months

Subjects were required to keep a symptom diary throughout the entire trial period from the start of investigational medicinal product (IMP) administration in the washout period until the end of the treatment period. Assessment items included scores for shortness of breath, cough, and sputum, IMP compliance, use of salbutamol and respiratory symptom medications, and smoking status. Subjects recorded a score of between 0 and 3, with 0 indicating no symptoms and 3 indicating a high level of symptoms, for each domain.

Change From Baseline at 24 Months in St. George's Respiratory Questionnaire (SGRQ) Total ScoreBaseline, 24 months

The SGRQ is a self-administered questionnaire designed to measure and quantify the impact of chronic respiratory disease on health-related quality of life (QOL) and well-being in three domains: symptoms, activity, and impact on daily life. The SGRQ was completed by each subject prior to IMP administration at baseline and at Month 6, Month 12, Month 18, and Month 24 (end of treatment).

A weighted score based on population norms for each dimension and total was evaluated. Scores were expressed as a percentage of overall impairment where 100 represented worst possible health status and 0 indicated best possible health status. Scores were calculated when less than 24% of the item scores were missing, otherwise the scores were set to missing. Where there were multiple answers for a question, the worst case was used.

© Copyright 2025. All Rights Reserved by MedPath